Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.

Chen SY, Wu JY, Liao KM, Lin YM

European heart journal. Cardiovascular pharmacotherapy1 Jul 2025Cited by 6 (Europe PMC)

PMID39963713PMCIDPMC12231126DOI10.1093/ehjcvp/pvaf014PepBankPUB-39963713

Summary

AimsManaging patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) is challenging. While sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show cardiovascular benefits, the impact of combining these agents is unclear. This study evaluated whether adding GLP-1 RA to SGLT2i provides additional benefits in patients with both ASCVD and HF.Methods and resultsThis retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024. A total of 2 797 317 patients were identified, with 96 051 patients meeting inclusion criteria. After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE). Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone. Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect. Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.ConclusionsIn ASCVD and HF patients, adding GLP-1 RA to SGLT2i reduces 1-year mortality and hospitalization, warranting further investigation in diverse settings.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study28

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In the semaglutide plus SGLT2 inhibitor subgroup of patients with ASCVD and heart failure, analyses showed consistent benefits versus SGLT2 inhibitor alone.
In plain wordsIn people with ASCVD and heart failure, the semaglutide-plus-SGLT2 subgroup showed consistent benefits versus SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
Direction not reportedCardiovascular outcomes
Study
n: not reported in source
Comparator
SGLT2i alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
Show in the study text Report a problemFND-3996371309
02HumanObservational studyEfficacy outcome
In the liraglutide plus SGLT2 inhibitor subgroup of patients with ASCVD and heart failure, analyses showed a neutral effect versus SGLT2 inhibitor alone.
In plain wordsIn people with ASCVD and heart failure, the liraglutide-plus-SGLT2 subgroup showed a neutral effect versus SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
Direction not reportedCardiovascular outcomes
Study
n: not reported in source
Comparator
SGLT2i alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
Show in the study text Report a problemFND-3996371310
03HumanObservational studyEfficacy outcome
In patients with ASCVD and heart failure, dulaglutide added to SGLT2i showed consistent prognostic benefit versus SGLT2i alone.
In plain wordsIn patients with artery disease and heart failure, dulaglutide plus SGLT2 inhibitors showed benefit compared with SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDulaglutide subgroup prognostic benefit
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Show in the study text Report a problemFND-3996371327

Studies that did not test the peptide alone25

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year mortality or hospitalization than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year death or hospitalization than SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
DecreaseMortality or hospitalization
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.74 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371301
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year mortality or hospitalization than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year death or hospitalization than SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
DecreaseMortality or hospitalization
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.74 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371302
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, pooled GLP-1RA plus SGLT2i use was linked to less mortality or hospitalization than SGLT2i alone.
In plain wordsIn patients with artery disease and heart failure, pooled GLP-1 drugs plus SGLT2 inhibitors showed fewer deaths or hospitalizations than SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMortality or hospitalization
Study
n = 10,544
Comparator
SGLT2 inhibitor alone
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.78 ratio
mortality or hospitalization
95% CI of hazard ratio
0.74 to 0.83 ratio
mortality or hospitalization
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3996371323
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year mortality than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year death than SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
DecreaseMortality
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Measurements
HR
0.72
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.62 to 0.84
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371303
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year mortality than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year death than SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
DecreaseMortality
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Measurements
HR
0.72
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.62 to 0.84
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371304
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year hospitalization than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year hospitalization than SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
DecreaseHospitalization
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.73 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371305
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year hospitalization than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year hospitalization than SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
DecreaseHospitalization
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.78
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.73 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371306
11HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year heart-failure exacerbation than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year heart-failure exacerbations than SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
DecreaseHeart failure exacerbation
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
HR
0.77
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.72 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371307
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, GLP-1 receptor agonist plus SGLT2 inhibitor therapy was linked to lower 1-year heart-failure exacerbation than SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, pooled GLP-1-plus-SGLT2 treatment was linked to lower one-year heart-failure exacerbations than SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
DecreaseHeart failure exacerbation
Study
n = 10,544
Comparator
SGLT2i alone
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
HR
0.77
GLP-1RA plus SGLT2i versus SGLT2i alone; 95% CI 0.72 to 0.83
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371308
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, pooled GLP-1RA plus SGLT2i use was linked to lower mortality than SGLT2i alone.
In plain wordsIn patients with heart failure, pooled GLP-1 drugs plus SGLT2 inhibitors were linked to fewer deaths than SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMortality
Study
n = 10,544
Comparator
SGLT2 inhibitor alone
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Measurements
Hazard ratio
0.72 ratio
mortality
95% CI of hazard ratio
0.62 to 0.84 ratio
mortality
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3996371324
14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, pooled GLP-1RA plus SGLT2i use was linked to less hospitalization than SGLT2i alone.
In plain wordsIn patients with heart failure, pooled GLP-1 drugs plus SGLT2 inhibitors were linked to fewer hospitalizations than SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHospitalization
Study
n = 10,544
Comparator
SGLT2 inhibitor alone
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.78 ratio
hospitalization
95% CI of hazard ratio
0.73 to 0.83 ratio
hospitalization
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3996371325
15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with ASCVD and heart failure, pooled GLP-1RA plus SGLT2i use was linked to fewer heart failure exacerbations than SGLT2i alone.
In plain wordsIn patients with heart failure, pooled GLP-1 drugs with SGLT2 inhibitors were linked to fewer exacerbations than SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHeart failure exacerbation
Study
n = 10,544
Comparator
SGLT2 inhibitor alone
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Measurements
Hazard ratio
0.77 ratio
heart failure exacerbation
95% CI of hazard ratio
0.72 to 0.83 ratio
heart failure exacerbation
Source sentences
Summary
Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3996371326
16HumanNot a test of Liraglutide aloneObservational studySafety outcome
In patients with ASCVD and heart failure, drug-related side effects were not significantly different between GLP-1 receptor agonist plus SGLT2 inhibitor therapy and SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, side effects did not differ significantly between pooled GLP-1-plus-SGLT2 treatment and SGLT2 treatment alone.
Peptide
Liraglutide
Outcome
No significant changeDrug-related side effects
Study
n = 10,544
Comparator
SGLT2i alone
Outcome group
Adverse events · Whole body
Source sentences
Summary
Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371311
17HumanNot a test of Semaglutide aloneObservational studySafety outcome
In patients with ASCVD and heart failure, drug-related side effects were not significantly different between GLP-1 receptor agonist plus SGLT2 inhibitor therapy and SGLT2 inhibitor alone.
In plain wordsIn ASCVD/HF patients, side effects did not differ significantly between pooled GLP-1-plus-SGLT2 treatment and SGLT2 treatment alone.
Peptide
Semaglutide
Outcome
No significant changeDrug-related side effects
Study
n = 10,544
Comparator
SGLT2i alone
Outcome group
Adverse events · Whole body
Source sentences
Summary
Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371312
18HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In patients with ASCVD and heart failure, drug-related side effects were similar with pooled GLP-1RA plus SGLT2i and SGLT2i alone.
In plain wordsIn patients with heart failure, pooled GLP-1 drugs with SGLT2 inhibitors showed similar side effects to SGLT2 inhibitors alone.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeDrug-related side effects
Study
n = 10,544
Comparator
SGLT2 inhibitor alone
Outcome group
Adverse events · Whole body
Source sentences
Summary
Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3996371328
19HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with HFpEF, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with HFpEF, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported clinical benefits in HFpEF subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371313
20HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with HFpEF, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with HFpEF, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedReported clinical benefits in HFpEF subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371314
21HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with HFrEF, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with HFrEF, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported clinical benefits in HFrEF subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371315
22HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with HFrEF, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with HFrEF, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedReported clinical benefits in HFrEF subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371316
23HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with diabetes, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with diabetes, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported clinical benefits in diabetes subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371317
24HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with diabetes, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with diabetes, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedReported clinical benefits in diabetes subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371318
25HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with obesity, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with obesity, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported clinical benefits in obesity subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371319
26HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with obesity, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with obesity, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedReported clinical benefits in obesity subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371320
27HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with chronic kidney disease, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with chronic kidney disease, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedReported clinical benefits in chronic kidney disease subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3996371321
28HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In ASCVD/HF patients with chronic kidney disease, pooled GLP-1RA-plus-SGLT2 therapy showed consistent reported benefits versus SGLT2 alone; the subgroup endpoint, signed estimate and N were unstated.
In plain wordsIn ASCVD/HF patients with chronic kidney disease, pooled GLP-1-plus-SGLT2 treatment showed benefits versus SGLT2 alone; the subgroup endpoint was unspecified.
Peptide
Semaglutide
Outcome
Direction not reportedReported clinical benefits in chronic kidney disease subgroup
Study
n: not reported in source
Comparator
SGLT2 inhibitor alone
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024.
Summary · context
Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3996371322

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 10Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 4
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.